If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
For people with relapsed or refractory diffuse large B-cell lymphoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
It is the first autotaxin inhibitor to be investigated in cancer patients
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Subscribe To Our Newsletter & Stay Updated
